COVID-19 and Cardiovascular Disease: From Bench to Bedside.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 33856918.
- Also identified by DOI 10.1161/CIRCRESAHA.121.317997 and PMC identifier 8048382.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A pandemic of historic impact, coronavirus disease 2019 (COVID-19) has potential consequences on the cardiovascular health of millions of people who survive infection worldwide. Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the etiologic agent of COVID-19, can infect the heart, vascular tissues, and circulating cells through ACE2 (angiotensin-converting enzyme 2), the host cell receptor for the viral spike protein. Acute cardiac injury is a common extrapulmonary manifestation of COVID-19 with potential chronic consequences. This update provides a review of the clinical manifestations of cardiovascular involvement, potential direct SARS-CoV-2 and indirect immune response mechanisms impacting the cardiovascular system, and implications for the management of patients after recovery from acute COVID-19 infection.
Medical subject headings
- Angiotensin-Converting Enzyme 2
- COVID-19
- Cardiovascular Diseases
- Myocytes, Cardiac
- SARS-CoV-2
- Virus Internalization